Harrow, a leading provider of ophthalmic disease management solutions in North America, announced significant leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as the Chief Executive Officer, bringing over 20 years of leadership experience in the healthcare and pharmaceutical industries. His track record includes transformative growth, launching market-shaping products, and scaling businesses within the pharmaceutical sector.
Bridseida Cruz has been appointed as the Head of Quality at ImprimisRx, bringing over 25 years of experience in leading quality and operations in 503b outsourcing, pharmaceutical, and medical device organizations. She is recognized for driving FDA remediation, ensuring compliance sustainability, and building high-performing teams.
These appointments come as Harrow aims to position itself as the next great U.S. ophthalmic company, with a vision to fulfill the unmet needs of U.S. eyecare professionals. ImprimisRx, known as a trusted national leader in ophthalmic compounding, has become the gold standard innovator, providing critical and affordable medicines benefiting millions of Americans over the past decade.
The new leadership is expected to lead ImprimisRx into its next operational phase, as the company continues to innovate and address conditions affecting both the front and back of the eye. Harrow's commitment is to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.
These changes in leadership signal a significant shift in strategy and vision for ImprimisRx, with the expectation of driving transformative growth and further innovation in the ophthalmic pharmaceutical space. As a result of these announcements, the company's shares have moved -4.82% on the market, and are now trading at a price of $45.43. Check out the company's full 8-K submission here.
